Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin ophthalmic - MC2 Therapeutics

Next Previous
Drug Profile

Ciclosporin ophthalmic - MC2 Therapeutics

Alternative Names: MC2-03; PADciclo 0.03%; PADciclo™; PAD™cyclosporine

Latest Information Update: 30 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MC2 Biotek
  • Developer MC2 Therapeutics; Moorfields Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Dry eyes

Most Recent Events

  • 30 Nov 2022 NDR Batch#26; According to November 2022 pipeline company plan phase III trial in 2022.
  • 03 Jun 2020 Efficacy data from a phase II NORTHERN LIGHTS trial in Dry eye were presented at the 21st Annual Congress of the European League Against Rheumatism (EULAR-2020)
  • 31 Jan 2020 MC2 Therapeutics plans a phase III trials in Dry eyes in H2 2022 (MC2 Therapeutics pipeline, July 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top